ArticleInternational journal of medical sciences2025
Drug Interaction of Dasatinib with Thymoquinone: A Pharmacokinetic Study in Rats.
Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib (DAS), a multi-kinase inhibitor targeting Src and BCR-ABL families, is approved for Ph+ acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CML). Its metabolism by CYP3A4 and transported by efflux pump P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) render it susceptible to drug, food, and herbal interactions. This study investigated the potential impact of thymoquinone (TQ) co-administration on dasatinib pharmacokinetics (PK) and the subsequent risk of altered efficacy or toxicity. Wistar rats were pretreated with a daily oral dose of TQ (40 mg/kg) for one week before receiving a single oral dose of DAS (25 mg/kg). Blood samples were collected at different time points, and plasma concentrations of DAS were measured using UPLC-MS/MS. A non-compartmental analysis was applied to calculate the PK parameters of DAS. Additionally, the impact of TQ treatment on hepatic and intestinal protein expressions of CYP3A4, Pgp and BCRP were investigated using Western blot analysis. TQ pretreatment significantly altered the disposition of DAS in animals as compared to untreated animals. More specifically, a substantial increase in DAS Cmax (213.26%), AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.